NCT01968109 2026-04-06
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
Clinical Trials
28 trialsNCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03656718 2025-11-12
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03963518 2025-10-06
SURROGATE-ICI
Institut Bergonié
Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02775292 2025-07-30
NYM
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT03570619 2025-05-08
IMPACT
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT05043714 2025-03-24
NEBULA
Akamis Bio
Phase 1 Completed
NCT04761198 2025-03-17
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Mereo BioPharma
Phase 1/2 Completed
NCT02966548 2025-02-17
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03406871 2025-01-24
REGONIVO
National Cancer Center Hospital East
Phase 1 Completed
NCT04187833 2025-01-14
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03296137 2024-10-26
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Phase 1/2 Completed
NCT03525925 2024-03-18
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02467361 2023-11-14
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02904226 2023-07-03
ICONIC
Jounce Therapeutics, Inc.
Phase 1/2 Completed
NCT03396211 2023-04-07
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Elevar Therapeutics
Phase 1 Completed
NCT04112498 2023-04-06
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
Bristol-Myers Squibb
Phase 1 Completed
NCT03431948 2023-02-16
C4-MOSART
University of Chicago
Phase 1 Completed
NCT03453892 2023-02-16
ST-ICI
University of Erlangen-Nürnberg Medical School
Completed
NCT01714739 2023-02-02
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02832167 2022-05-09
CheckMate 627
Bristol-Myers Squibb
Phase 2 Completed
NCT03271047 2022-01-04
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Pfizer
Phase 2 Completed
NCT02213289 2021-04-08
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
University of Chicago
Phase 2 Completed
NCT02534506 2020-05-18
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT01629758 2015-03-06
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed